Illumina's TruSight HLA

Mar 05, 2015

Illumina has launched its TruSight HLA, a sequencing-based solution for accurate HLA typing across thousands of known and novel HLA alleles. The kit includes the TruSight HLA Sequencing Panel, a single assay for ultra-high resolution analysis of all the key genes within the major histocompatibility complex, reagents for preparing and sequencing DNA libraries, and optimized data analysis with software from Conexio Genomics.

Breaking News

Plasmid Transfer Let Cholera Pathogen in Yemen Become Multidrug Resistant, Study Suggests
Harbinger Health Raises $140 Million in Series B Financing
BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing
Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements
Genetic Overlap Between Schizophrenia, Cardiovascular Disease Risk Uncovered by GWAS Analysis

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.